Yi Sing Gee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yi Sing Gee has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Christopher J. T. Hyland
School of Science, Molecular Horizons Research Institute University of Wollongong Wollongong New South Wales Australia
5 shared publications - Jonathan Bayldon Baell
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
4 shared publications - Michael G. Gardiner
Research School of Chemistry Australian National University Canberra ACT 2601 Australia
3 shared publications - Amandeep Kaur
Medicinal Chemistry Monash Institute of Pharmaceutical Sciences Monash University Melbourne VIC Australia
2 shared publications - Daniel J. Rivinoja
CSchool of Chemistry, University of Wollongong, Wollongong, NSW 2522, Australia
2 shared publications - Eric Tran
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences
2 shared publications
Latest Publications
- Open Access
Fanconi Anaemia E3 Ligase complex activity is regulated by a druggable metabolite binding site in FANCX
The Fanconi anaemia (FA) DNA repair pathway is an emerging target for precision cancer therapy. Using a high-throughput FANCD2-monoubiquitination assay, we identified a class of small molecules, including MSG010, that inhibit the FA E3 ligase complex in vitro . Because these molecules, and the metabolite, palmitoyl-CoA, are known to engage allosteric drug and metabolite (ADaM) binding site in AMP-activated kinase (AMPK), we hypothesised that a similar pocket exists within the FA complex. Supporting this, long-chain, but not short-chain, fatty acyl-CoA molecules inhibited the FA E3 ligase complex activity, and sequence analysis revealed similarity between the AMPK ADaM site and a WD40 repeat in the FA subunit FANCX. Targeted mutagenesis of this FANCX region disrupted E3 ligase activity or abolished inhibition by MSG010, suggesting the presence of an ADaM-like site in FANCX. Moreover, MSG010 preferentially killed BRCA1 -deficient cells in vitro . These findings identify a putative small-molecule binding site in the FA pathway that may be developed further to test for exploitation as anticancer therapeutics.
Open AccessFanconi Anaemia E3 Ligase complex activity is regulated by a druggable metabolite binding site in FANCX
The Fanconi anaemia (FA) DNA repair pathway is an emerging target for precision cancer therapy. Using a high-throughput FANCD2-monoubiquitination assay, we identified a class of small molecules, including MSG010, that inhibit the FA E3 ligase complex in vitro . Because these molecules, and the metabolite, palmitoyl-CoA, are known to engage allosteric drug and metabolite (ADaM) binding site in AMP-activated kinase (AMPK), we hypothesised that a similar pocket exists within the FA complex. Supporting this, long-chain, but not short-chain, fatty acyl-CoA molecules inhibited the FA E3 ligase complex activity, and sequence analysis revealed similarity between the AMPK ADaM site and a WD40 repeat in the FA subunit FANCX. Targeted mutagenesis of this FANCX region disrupted E3 ligase activity or abolished inhibition by MSG010, suggesting the presence of an ADaM-like site in FANCX. Moreover, MSG010 preferentially killed BRCA1 -deficient cells in vitro . These findings identify a putative small-molecule binding site in the FA pathway that may be developed further to test for exploitation as anticancer therapeutics.
- Open Access
- 6 April 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 312, 118838
Discovery of APO-50815, a potent WEE1 kinase inhibitor with exceptional efficacy against patient-derived colorectal cancer organoids
- 6 April 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 312, 118838
Open AccessDiscovery of APO-50815, a potent WEE1 kinase inhibitor with exceptional efficacy against patient-derived colorectal cancer organoids
- Open Access
- 29 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 2082-2114
Biological Activity and Structural Biology of Current KAT6A Inhibitor Chemotypes
All lysine acetyltransferases (KATs) modulate biological outcomes through the acetylation of lysine side-chain amino groups facilitated by acetyl coenzyme A (AcCoA). KAT6A belongs to the class of MYST domain histone acetyltransferases (HATs), which had been regarded as undruggable. The first on-target KAT6A inhibitors with in vivo activity were reported in 2018, catalyzing intense industry interest in this enzyme as an oncology target. In this study, we experimentally evaluated representative KAT6A inhibitor chemotypes through resynthesis and comparative biochemical assays, cellular assays, and structural biology. We outline the recent history of each KAT6A inhibitor chemotype discovery, including SAR for potency, selectivity, and cellular activity. We extensively benchmark key compounds from each chemotype, augmented by new acylsulfonohydrazide analogues and a novel fused [1,2,4]thiadiazine KAT6A inhibitor subclass, which we report here for the first time, along with co-crystal structures. Additionally, we report on the in vivo activity, pharmacokinetics, and toxicology profiles of these inhibitors.
- 29 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 2082-2114
Open AccessBiological Activity and Structural Biology of Current KAT6A Inhibitor Chemotypes
All lysine acetyltransferases (KATs) modulate biological outcomes through the acetylation of lysine side-chain amino groups facilitated by acetyl coenzyme A (AcCoA). KAT6A belongs to the class of MYST domain histone acetyltransferases (HATs), which had been regarded as undruggable. The first on-target KAT6A inhibitors with in vivo activity were reported in 2018, catalyzing intense industry interest in this enzyme as an oncology target. In this study, we experimentally evaluated representative KAT6A inhibitor chemotypes through resynthesis and comparative biochemical assays, cellular assays, and structural biology. We outline the recent history of each KAT6A inhibitor chemotype discovery, including SAR for potency, selectivity, and cellular activity. We extensively benchmark key compounds from each chemotype, augmented by new acylsulfonohydrazide analogues and a novel fused [1,2,4]thiadiazine KAT6A inhibitor subclass, which we report here for the first time, along with co-crystal structures. Additionally, we report on the in vivo activity, pharmacokinetics, and toxicology profiles of these inhibitors.
- 4 September 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (9) , 6746-6754
Nitroreductase-Activated Probes for Monitoring Hypoxia
Hypoxia, a hallmark of solid tumors, complicates cancer treatment by reducing the efficacy of radiotherapy and chemotherapy. To optimize strategies for hypoxia detection and targeted cancer therapy, this work explores the development of hypoxia-responsive fluorescent probes. In this study, we compared various nitroaromatic groups and both elimination-based and cyclization-based self-immolative designs to study nitroreductase (NTR) activation. The research highlighted differences in activation response among the probes, with elimination-based probes (8b-8d) showing faster activation compared to cyclization-based probes (8f-8i). Furthermore, analogs with different nitroaromatic linkers exhibited different selectivity profiles for common biomolecules and ions. These subtle differences were also apparent in our cellular hypoxia assays, underscoring the importance of carefully selecting the nitroaromatic moiety and probe/drug design for applications such as diagnostic tools to detect hypoxia or targeted cancer therapies.
- 4 September 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (9) , 6746-6754
Nitroreductase-Activated Probes for Monitoring Hypoxia
Hypoxia, a hallmark of solid tumors, complicates cancer treatment by reducing the efficacy of radiotherapy and chemotherapy. To optimize strategies for hypoxia detection and targeted cancer therapy, this work explores the development of hypoxia-responsive fluorescent probes. In this study, we compared various nitroaromatic groups and both elimination-based and cyclization-based self-immolative designs to study nitroreductase (NTR) activation. The research highlighted differences in activation response among the probes, with elimination-based probes (8b-8d) showing faster activation compared to cyclization-based probes (8f-8i). Furthermore, analogs with different nitroaromatic linkers exhibited different selectivity profiles for common biomolecules and ions. These subtle differences were also apparent in our cellular hypoxia assays, underscoring the importance of carefully selecting the nitroaromatic moiety and probe/drug design for applications such as diagnostic tools to detect hypoxia or targeted cancer therapies.
- Open Access
- 25 October 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (24) , e202400482
Phenotypic‐Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis
Tuberculosis remains a leading cause of death by infectious disease. The long treatment regimen and the spread of drug‐resistant strains of the causative agent Mycobacterium tuberculosis (Mtb) necessitates the development of new treatment options. In a phenotypic screen, nitrofuran‐resorufin conjugate 1 was identified as a potent sub‐micromolar inhibitor of whole cell Mtb. Complete loss of activity was observed for this compound in Mtb mutants affected in enzyme cofactor F420 biosynthesis (fbiC), suggesting that 1 undergoes prodrug activation in a manner similar to anti‐tuberculosis prodrug pretomanid. Exploration of the structure‐activity relationship led to the discovery of novel resorufin analogues that do not rely on the deazaflavin‐dependent nitroreductase (Ddn) bioactivation pathway for their antimycobacterial activity. These analogues are of interest as they work through an alternative, currently unknown mechanism that may expand our chemical arsenal towards the treatment of this devastating disease.
- 25 October 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (24) , e202400482
Open AccessPhenotypic‐Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis
Tuberculosis remains a leading cause of death by infectious disease. The long treatment regimen and the spread of drug‐resistant strains of the causative agent Mycobacterium tuberculosis (Mtb) necessitates the development of new treatment options. In a phenotypic screen, nitrofuran‐resorufin conjugate 1 was identified as a potent sub‐micromolar inhibitor of whole cell Mtb. Complete loss of activity was observed for this compound in Mtb mutants affected in enzyme cofactor F420 biosynthesis (fbiC), suggesting that 1 undergoes prodrug activation in a manner similar to anti‐tuberculosis prodrug pretomanid. Exploration of the structure‐activity relationship led to the discovery of novel resorufin analogues that do not rely on the deazaflavin‐dependent nitroreductase (Ddn) bioactivation pathway for their antimycobacterial activity. These analogues are of interest as they work through an alternative, currently unknown mechanism that may expand our chemical arsenal towards the treatment of this devastating disease.
- Open Access
- 28 December 2018
- Published by Wiley in Journal of Neurochemistry
- Vol. 149 (4) , 535-550
Novel dual‐action prodrug triggers apoptosis in glioblastoma cells by releasing a glutathione quencher and lysine‐specific histone demethylase 1A inhibitor
Targeting epigenetic mechanisms has shown promise against several cancers but has so far been unsuccessful against glioblastoma (GBM). Altered histone 3 lysine 4 methylation and increased lysine‐specific histone demethylase 1A (LSD1) expression in GBM tumours nonetheless suggest that epigenetic mechanisms are involved in GBM. We engineered a dual‐action prodrug, which is activated by the high hydrogen peroxide levels associated with GBM cells. This quinone methide phenylaminecyclopropane prodrug releases the LSD1 inhibitor 2‐phenylcyclopropylamine with the glutathione scavenger para‐quinone methide to trigger apoptosis in GBM cells. Quinone methide phenylaminocyclopropane impaired GBM cell behaviours in two‐dimensional and three‐dimensional assays, and triggered cell apoptosis in several primary and immortal GBM cell cultures. These results support our double‐hit hypothesis of potentially targeting LSD1 and quenching glutathione, in order to impair and kill GBM cells but not healthy astrocytes. Our data suggest this strategy is effective at selectively targeting GBM and potentially other types of cancers.Open science badges: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/. image
- 28 December 2018
- Published by Wiley in Journal of Neurochemistry
- Vol. 149 (4) , 535-550
Open AccessNovel dual‐action prodrug triggers apoptosis in glioblastoma cells by releasing a glutathione quencher and lysine‐specific histone demethylase 1A inhibitor
Targeting epigenetic mechanisms has shown promise against several cancers but has so far been unsuccessful against glioblastoma (GBM). Altered histone 3 lysine 4 methylation and increased lysine‐specific histone demethylase 1A (LSD1) expression in GBM tumours nonetheless suggest that epigenetic mechanisms are involved in GBM. We engineered a dual‐action prodrug, which is activated by the high hydrogen peroxide levels associated with GBM cells. This quinone methide phenylaminecyclopropane prodrug releases the LSD1 inhibitor 2‐phenylcyclopropylamine with the glutathione scavenger para‐quinone methide to trigger apoptosis in GBM cells. Quinone methide phenylaminocyclopropane impaired GBM cell behaviours in two‐dimensional and three‐dimensional assays, and triggered cell apoptosis in several primary and immortal GBM cell cultures. These results support our double‐hit hypothesis of potentially targeting LSD1 and quenching glutathione, in order to impair and kill GBM cells but not healthy astrocytes. Our data suggest this strategy is effective at selectively targeting GBM and potentially other types of cancers.Open science badges: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/. image
- 12 November 2017
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 82 (24) , 13517-13529
Pd-Catalyzed Dearomative [3 + 2] Cycloaddition of 3-Nitroindoles with 2-Vinylcyclopropane-1,1-dicarboxylates
A trans-diastereoselective Pd-catalyzed dearomative [3 + 2] cycloaddition between vinylcyclopropane dicarboxylates and 3-nitroindoles has been developed. The reaction provides densely functionalized cyclopenta[b]indolines with versatile vinyl and nitro-groups. The addition of a halide additive was found to be critical for the diastereoselectivity of the reaction, which is proposed to be a result of a rapid π-σ-π interconversion between the intermediates allowing for Curtin–Hammett control. A switch in diastereoselectivity to afford products with the vinyl and nitro groups cis to each other is observed with a 4-substituted 3-nitroindole.
- 12 November 2017
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 82 (24) , 13517-13529
Pd-Catalyzed Dearomative [3 + 2] Cycloaddition of 3-Nitroindoles with 2-Vinylcyclopropane-1,1-dicarboxylates
A trans-diastereoselective Pd-catalyzed dearomative [3 + 2] cycloaddition between vinylcyclopropane dicarboxylates and 3-nitroindoles has been developed. The reaction provides densely functionalized cyclopenta[b]indolines with versatile vinyl and nitro-groups. The addition of a halide additive was found to be critical for the diastereoselectivity of the reaction, which is proposed to be a result of a rapid π-σ-π interconversion between the intermediates allowing for Curtin–Hammett control. A switch in diastereoselectivity to afford products with the vinyl and nitro groups cis to each other is observed with a 4-substituted 3-nitroindole.
- 4 January 2017
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 7 (2) , 1053-1056
The Diastereoselective Synthesis of Pyrroloindolines by Pd-Catalyzed Dearomative Cycloaddition of 1-Tosyl-2-vinylaziridine to 3-Nitroindoles
- 4 January 2017
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 7 (2) , 1053-1056
The Diastereoselective Synthesis of Pyrroloindolines by Pd-Catalyzed Dearomative Cycloaddition of 1-Tosyl-2-vinylaziridine to 3-Nitroindoles
- 20 January 2016
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 14 (8) , 2498-2503
Oxidative ring-opening of ferrocenylcyclopropylamines to N-ferrocenylmethyl β-hydroxyamides
The in situ reduction of ferrocenyl cyclopropylimines to the corresponding amines triggers a facile oxidative ring-opening to yield the formal four-electron oxidation products: N-ferrocenylmethyl β-hydroxyamides. This process is believed to proceed via generation of a ferrocinium ion in the presence of air, leading to facile formation of a distonic radical cation that is ultimately trapped by oxygen.
- 20 January 2016
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 14 (8) , 2498-2503
Oxidative ring-opening of ferrocenylcyclopropylamines to N-ferrocenylmethyl β-hydroxyamides
The in situ reduction of ferrocenyl cyclopropylimines to the corresponding amines triggers a facile oxidative ring-opening to yield the formal four-electron oxidation products: N-ferrocenylmethyl β-hydroxyamides. This process is believed to proceed via generation of a ferrocinium ion in the presence of air, leading to facile formation of a distonic radical cation that is ultimately trapped by oxygen.
- 18 July 2013
- Published by Royal Society of Chemistry (RSC) in Annu. Rep. Prog. Chem., Sect. B: Org. Chem.
- Vol. 109, 103-125
Synthetic methods: part (ii) oxidation and reduction methods
This report highlights selected advances in some of the most commonly used oxidation and reduction reactions, focusing on the literature from 2012. The structure of this review follows that of the previous years report (J. K. Howard and C. J. T. Hyland, Annu. Rep. Prog. Chem., Sect. B: Org. Chem., 2012, 108, 29–52 (). In the field of oxidation a number of important advances have been made. Notably, the group of Miller has reported a peptide-based catalyst that allows the selective epoxidation of polyenes (P. A. Lichtor and S. J. Miller, Nat. Chem., 2012, 4, 990). Meanwhile, the Tomkinson group has reported osmium-free alkene dihydroxylation reactions with cyclopropyl-derived malonoyl peroxides (S. Picon, M. Rawling, M. Campbell and N. C. O. Tomkinson, Org. Lett., 2012, 14, 6250–6253). In the area of reduction methods the Chirik group has made an exciting breakthrough in the use of non-precious metal enantiopure C1-symmetric bis(imino)pyridine cobalt complexes for asymmetric hydrogenation of a range of styrene derivatives in up to 96% ee (S. Monfette, Z. R. Turner, S. P. Semproni and P. J. Chirik, J. Am. Chem. Soc., 2012, 134, 4561–4564). Meanwhile Kuwano et al. have reported the first PhTrap-ruthenium catalysed asymmetric hydrogenation of naphthalenes (R. Kuwano, R. Morioka, M. Kashiwabara and N. Kameyama, Angew. Chem., Int. Ed., 2012, 51, 4136–4139).
- 18 July 2013
- Published by Royal Society of Chemistry (RSC) in Annu. Rep. Prog. Chem., Sect. B: Org. Chem.
- Vol. 109, 103-125
Synthetic methods: part (ii) oxidation and reduction methods
This report highlights selected advances in some of the most commonly used oxidation and reduction reactions, focusing on the literature from 2012. The structure of this review follows that of the previous years report (J. K. Howard and C. J. T. Hyland, Annu. Rep. Prog. Chem., Sect. B: Org. Chem., 2012, 108, 29–52 (). In the field of oxidation a number of important advances have been made. Notably, the group of Miller has reported a peptide-based catalyst that allows the selective epoxidation of polyenes (P. A. Lichtor and S. J. Miller, Nat. Chem., 2012, 4, 990). Meanwhile, the Tomkinson group has reported osmium-free alkene dihydroxylation reactions with cyclopropyl-derived malonoyl peroxides (S. Picon, M. Rawling, M. Campbell and N. C. O. Tomkinson, Org. Lett., 2012, 14, 6250–6253). In the area of reduction methods the Chirik group has made an exciting breakthrough in the use of non-precious metal enantiopure C1-symmetric bis(imino)pyridine cobalt complexes for asymmetric hydrogenation of a range of styrene derivatives in up to 96% ee (S. Monfette, Z. R. Turner, S. P. Semproni and P. J. Chirik, J. Am. Chem. Soc., 2012, 134, 4561–4564). Meanwhile Kuwano et al. have reported the first PhTrap-ruthenium catalysed asymmetric hydrogenation of naphthalenes (R. Kuwano, R. Morioka, M. Kashiwabara and N. Kameyama, Angew. Chem., Int. Ed., 2012, 51, 4136–4139).